Novo Nordisk’s sharp decline may have opened the door for a massive rebound here’s why investors are watching its ...
Telehealth company Hims & Hers Health Inc. said late Monday it is in "active discussions" with Denmark's Novo Nordisk A/S to make Wegovy available on its platform.
Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United ...
Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...
Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of ...
Novo Nordisk attempts to acquire weight-loss drug company Metsera during government shutdown, potentially avoiding FTC antitrust review and regulatory scrutiny.
Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and ...
Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.
Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.
Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results